A survey on incidental adrenal tumors in Japan, The Journal of Urology, vol.147, pp.1478-1481, 1992. ,
Prevalence and natural history of adrenal incidentalomas, European Journal of Endocrinology, vol.149, pp.273-285, 2003. ,
, , 1997.
, Incidentalomas of the adrenal gland: diagnostic and therapeutic implications, The American Surgeon, vol.63
of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors, European Journal of Endocrinology, vol.175, pp.1-34, 2016. ,
,
Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.102, pp.2465-2472, 2017. ,
, , 2017.
, Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice, European Journal of Endocrinology, vol.177, pp.475-483
Long-term follow-up study of patients with adrenal incidentalomas, European Journal of Endocrinology, vol.147, pp.489-494, 2002. ,
Contemporary review of large adrenal tumors in a tertiary referral center, Anticancer Research, vol.34, pp.2581-2588, 2014. ,
Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics, European Journal of Endocrinology, vol.168, pp.235-241, 2013. ,
, Management of adrenal incidentaloma. Best Practice & Research, vol.23, pp.233-243, 2009.
Adrenal incidentaloma: report of 33 cases, Journal of Surgical Oncology, vol.70, 1999. ,
, Adrenal tumor size was between 4 and 6 cm in 66 patients (81.5%), and superior to 6 cm in 15 patients (18.5%). 44 patients had initial surgery, and 37 were followed
, Among the 44 patients who had initial surgery, the investigator's rationale to proceed to surgery was based on the tumor diameter in 17 (4.5%), and/or imaging characteristics in 36
, 24 had a follow-up superior to 3 years (mean, 47 months; min, 36; max, 71), ie. 13 patients were operated in the first 3 years after initial diagnosis: reasons for surgery were: tumor growth in 75% (n=9) cases, and/or unenhanced CT > 10 in 33.3% (n=4) cases and/or hypersecretion in 38
, Altogether, among the 65 operated patients (44 at diagnosis, and 21 during the follow-up, p.13
, Beside myelolipomas (n=2) and nonmalignant tumor, 3 (23%) had a spontaneous CT density < 10 UH and 5 (38%) had a wash-out > 45%
, Altogether, unenhanced CT < 10 showed 85.6% (CI95%=54.5-98.1) sensitivity and 78, p.8
, )). A relative wash-out of 45% showed 61, a CT density of 19 gave 69.2% sensitivity (CI95%=38.5-90.9, p.5
, 1) sensitivity and 92.3% specificity (CI95%=81.4-97.4); a wash out of 41% gave 61.5% sensitivity (CI95%=31.5-86.1), and 96, pp.95-126
, 5%) had a 18F-FDG uptake ratio > 1.5, with 3 non-secreting pheochromocytomas (18F-FDG uptake ratio =1.9, 3.1, 2.4), 2 non-secreting adrenal adenomas, and 1 myelolipoma. A 18F-FDG uptake ratio of 1, Among the 13 patients with a malignant tumor, all had a 18F-FDG uptake ratio > 1.5. In contrast, among the 52 patients with a benign tumor, vol.6, p.100
, 2-100) and a specificity of 92.3% (CI95%=81.4-97.8) (p<0.0001). The ROC curves for spontaneous CT density, wash out and 18F-FDG uptake ratio are depicted in additional figures 1, vol.2